Carna Health

What do the apps and the platform do?

Carna describes itself as "the AI-driven platform public and private healthcare systems deploy to detect, manage, and prevent Cardio-Kidney-Metabolic syndrome." The suite has a CKM Intelligence Platform, a Provider App and a Patient App.

The vendor says point-of-care devices return eGFR and uACR in under 15 minutes "with no lab or specialist required." Its predictive analytics "identifies which screened patients will likely progress to advanced CKD," flags high-risk people and suggests referral pathways. The Provider App offers AI-guided workflows and "specialist-grade recommendations on next steps, drug interactions, and evidence-based interventions," and care plans sync back to the EHR.

Around that sit a Patient 360 record, a Master Patient Index, a population module for hot-spots and cohort risk segmentation, and a multi-language Patient App with a risk dashboard and reminders. Data comes in from point-of-care devices, EHRs, HIEs, labs, wearables and social-needs sources over FHIR, HL7 and API.

Whose products carry the FDA clearances?

The FDA-cleared claim on the homepage refers to point-of-care devices from Siemens Healthineers, Carna's exclusive device integration. The kidneyintelX.dkd test in a Renalytix release is Renalytix's own, and the HEDIS outcome data in that release concerns the test. Carna's software is not described as cleared.

What has been screened so far?

A May 2026 release from partner Renalytix carries the scale claims. Undiagnosed CKD was found in "nearly 50% of a screened community in Bermuda," Carna is "enrolling 35,000 individuals in Cameroon," and a further 75,000-patient Cameroon program is "launching." These are vendor and partner statements, and no peer-reviewed paper on the platform is known.

The vendor reports a place on Fortune's "America's Most Innovative Companies 2026" list, number 12 in healthcare, and a Fast Company World Changing Ideas honorable mention. Its pages offer a demo request and publish no price.

Who founded Carna?

The footer names Carna Inc., and the privacy policy lists 131 Dartmouth Street in the United States. Salvatore G. Viscomi, MD, is CEO and Boris Berat is CTO. The founding year is not stated, and no funding round, amount or investor is named. The compliance wording is "HIPAA Compliant" and "SOC2 Ready" on AWS infrastructure, a readiness statement with no SOC 2 report named.

The verdict

The two deployments cited are a screened community in Bermuda and programs in Cameroon, and both are reported by Carna or its partner Renalytix. A ministry or national screening program is the setting they describe.